Blockade of Androgen-induced Malignant Phenotypes by Flutamide Administration in Human Salivary Duct Carcinoma Cells

Anticancer Res. 2016 Nov;36(11):6071-6075. doi: 10.21873/anticanres.11196.

Abstract

Background/aim: Androgens are known to play a critical role in prostate cancer progression, but their effect on malignant phenotypes in salivary gland cancer is unclear. The androgen-androgen receptor (AR) axis may be involved in malignant phenotypes of salivary duct carcinoma (SDC) cells and therefore may be a new target for SDC treatment. To test this hypothesis, we investigated the effect of the androgen 5α-dihydrotestosterone (DHT) on proliferation, migration, and invasiveness of SDC cells.

Materials and methods: We used a wound-healing assay to measure cell migration and a Boyden chamber invasion assay to investigate SDC cell invasive capacity.

Results: DHT treatment increased cell proliferation, migration, and invasion. However, treatment with flutamide, an AR inhibitor, blocked the effects of DHT.

Conclusion: These results suggest that the androgen-AR axis is involved in SDC malignancy and may be an effective therapeutic target for treatment of human SDC.

Keywords: Androgen; cell migration; invasion; salivary duct carcinoma; steroid hormone receptors.

MeSH terms

  • Androgen Antagonists / pharmacology*
  • Flutamide / pharmacology*
  • Humans
  • Male
  • Phenotype
  • Salivary Ducts / pathology*
  • Salivary Gland Neoplasms / drug therapy*
  • Salivary Gland Neoplasms / pathology

Substances

  • Androgen Antagonists
  • Flutamide